DOW JONES27,960.80-1031.61 -3.56%
S&P 5003,225.89-111.86 -3.35%
NASDAQ9,221.28-355.31 -3.71%

Bellicum Pharma Reports Presentation Of News Translational Data For BPX-601 At ASCO GI Cancers Symposium

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today presented new Phase 1 translational results for BPX-601 at the American Society of

Benzinga · 01/24/2020 12:35

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today presented new Phase 1 translational results for BPX-601 at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) in San Francisco. The poster titled “Tumor Infiltration and Cytokine Biomarkers of Prostate Stem Cell Antigen (PSCA)-Directed GoCAR-T Cells in Patients with Advanced Pancreatic Tumors” presented new data from a cohort treated with BPX-601 and a single dose of rimiducid that showed immunomodulation in both the periphery and tumor microenvironment and provided additional insights into surrogate biomarkers of iMC-mediated GoCAR-T® activity.

“These translational results further support the potential for BPX-601 and for our GoCAR™ platform in solid tumors,” stated Rick Fair, President and Chief Executive Officer, Bellicum Pharmaceuticals. “We are particularly encouraged by the findings of tumor infiltration and GoCAR-T mediated immunomodulation. We will look to build on these markers of activity in the next cohort of the study, which will evaluate repeat rimiducid dosing to reactivate BPX-601 cells over time. Initial results from this Cohort 5C are expected during the second half of this year.”

The poster at ASCO GI presented data from Cohort 5B of the study, consisting of 5 pancreatic cancer patients treated with BPX-601 and a single dose of rimiducid. The primary observations were:

  • BPX-601 GoCAR-T cells exhibited enhanced survival and persistence up to 9 months.
  • Activation of BPX-601 GoCAR-T cells mediated upregulation of immunomodulatory cytokines in patients.
  • BPX-601 GoCAR-T cells infiltrated metastatic pancreatic tumors.
  • Changes in tumor microenvironment gene expression consistent with a productive CAR-T cell immune response were observed in patients treated with BPX-601 GoCAR-T cells activated by rimiducid.